Active-ingredient Dossier
Denosumab
Active-ingredient Dossier for Denosumab (monoclonal antibody). Australian brands, products, PBS listings, PBAC outcomes — compiled by arcimedes.
- Brand: JUBBONTI
- Brand: WYOST
- Brand: XGEVA
- Brand: PROLIA
- Brand: DENOLIA
- Brand: DESKELTIA
- Therapeutic area: Musculoskeletal
- Therapeutic area: Oncology
What is
Denosumab Denosumab is a monoclonal antibody.
Australian brands containing
Denosumab — JUBBONTI — WYOST — XGEVA — DENOLIA — DESKELTIA — DEXEVA — DOSTIVA — PROLIA — OSPOMYV — XBORSO — CORORA — GANVADO
Therapeutic areas
Denosumab is registered in oncology (14 brands) and endocrinology (3 brands).
Sponsor landscape
Denosumab is marketed by five sponsors: Amgen, Accord Healthcare, Sandoz, Celltrion Healthcare, and Samsung Bioepis AU.
PBS and regulatory activity
Three brands containing denosumab have PBS-listed items, with the latest PBS schedule date of 1 May 2026. In the 2024–25 fiscal year, PBS expenditure on denosumab was approximately $307.4 million across 1.22 million scripts. The latest PBAC outcome was recorded on 1 November 2025, and the latest AusPAR was issued on 26 March 2026. Three brands have PBAC outcomes on record, and ten brands have AusPARs on record.